Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 6
Role of Rebiopsy at Disease Progression in EGFRm NSCLC
Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.
Video Player is loading.
Video content above is prompted by the following:
Regarding treatment sequencing, how do you approach second-line therapy after osimertinib monotherapy?
Related Content:
